2-溴-5-(3-羟基-戊烷-3-基)吡啶 | 874915-24-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-5-(3-羟基-戊烷-3-基)吡啶
• 英文名称: 2-bromo-5-(3-hydroxy-pentane-3-yl)pyridine
• 英文别名: 3-(6-bromopyridin-3-yl)pentan-3-ol；3-(6-Bromo-3-pyridyl)-3-pentanol
• CAS: 874915-24-9
• 化学式: C₁₀H₁₄BrNO
• 分子量: 244.131
• InChiKey: FQQWXDXQXXFOSY-UHFFFAOYSA-N

物化性质

• 沸点：
  337.0±27.0 °C(Predicted)
• 密度：
  1.359±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,5-二溴吡啶 、 3-戊酮 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 0.08h， 以68.8%的产率得到2-溴-5-(3-羟基-戊烷-3-基)吡啶
  参考文献：
  名称：

  Preparation of novel substituted haloarene compounds

  摘要：

  这项发明涉及一种新的制备式I或IV的新颖取代卤代芳烃化合物的过程：其中R1、R2、R3、R4、R5、X和Y如本文所定义，该过程包括一种新颖且高效的选择性对二卤代芳烃式II或V进行单锂化的步骤，通过在碳酰基试剂式III存在下使用有机锂化合物，其中R1和R2如本文所定义。在本发明的过程中，新形成的锂化卤代芳烃被碳酰基试剂原位顺序熄灭以形成所述的取代卤代芳烃。该过程适用于批处理或连续流系统。通过本发明的过程生产的取代卤代芳烃是制备N-芳基或N-杂环芳基取代的药用活性化合物的有用中间体，包括选择性5-羟色胺1（5-HT1）受体的拮抗剂、逆向激动剂和部分激动剂，用于治疗或预防抑郁症、焦虑症、强迫症（OCD）和其他需要5-HT1激动剂或拮抗剂的疾病。

  公开号：

  US20060030714A1

文献信息

• Substituted Biphenyl Derivative
  申请人：Kurata Hitoshi

  公开号：US20070275968A1

  公开（公告）日：2007-11-29

  The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: wherein R 1 represents a C 6 -C 10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C 1 -C 6 alkyl)amino group, a di-(C 1 -C 6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C 1 -C 6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R 2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R 3 represents a C 1 -C 6 alkyl group, and so on; and R 4 represents a C 1 -C 6 alkyl group, and so on.

  本发明涉及一种具有优异的胶原合成抑制活性的双芳基衍生物或其药学上可接受的盐。一种具有以下通式（I）所表示的结构或其药学上可接受的盐的双芳基衍生物：其中，R1代表一个C6-C10芳基基团，该基团被一个或三个独立选择的基团所取代，所述基团由公式R-L-、二（C1-C6烷基）氨基基团、二（C1-C6烷基）氨基磺酰基团、羟胺基甲酰基团、卤素原子等组成；R代表C1-C6烷基基团等；L代表磺酰基、氨基磺酰基或磺酰胺基等基团；R2代表氢原子等；A代表由公式（II）、（III）或（IV）所定义的基团；R3代表C1-C6烷基基团等；R4代表C1-C6烷基基团等。
• SUBSTITUTED BIPHENYL DERIVATIVE
  申请人：Sankyo Company, Limited

  公开号：EP1798229A1

  公开（公告）日：2007-06-20

  The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: wherein R1 represents a C6-C10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C1-C6 alkyl)amino group, a di-(C1-C6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C1-C6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R3 represents a C1-C6 alkyl group, and so on; and R4 represents a C1-C6 alkyl group, and so on.

  本发明涉及一种具有优异胶原合成抑制活性的生物芳基衍生物或其药理学上可接受的盐。一种具有下通式（I）所代表结构的生物芳基衍生物或其药理学上可接受的盐： 其中 R1代表C6-C10芳基，该芳基被一至三个各自独立地选自式R-L-定义的基团、二-(C1-C6烷基)氨基、二-(C1-C6烷基)氨基磺酰基、羟基氨基羰基和卤原子等组成的组取代；R 代表 C1-C6 烷基，以此类推；L 代表磺酰基、氨磺酰基或磺酰氨基，以此类推；R2 代表氢原子，以此类推；A 代表式（II）、（III）或（IV）定义的基团；R3 代表 C1-C6 烷基，以此类推；R4 代表 C1-C6 烷基，以此类推。
• PREPARATION OF NOVEL SUBSTITUTED HALOARENE COMPOUNDS
  申请人：Pfizer Products Inc.

  公开号：EP1771419A1

  公开（公告）日：2007-04-11
• US7273938B2
  申请人：——

  公开号：US7273938B2

  公开（公告）日：2007-09-25
• [EN] PREPARATION OF NOVEL SUBSTITUTED HALOARENE COMPOUNDS<br/>[FR] PREPARATION DE NOUVEAUX COMPOSES A BASE D'HALOARENES SUBSTITUES
  申请人：PFIZER PROD INC

  公开号：WO2006011030A1

  公开（公告）日：2006-02-02

  This invention relates to a new process for the preparation of novel substituted haloarene compounds of the formula I or IV: respectively, wherein R1, R2, R3, R4, R5, X, and Y are as defined herein, that comprises a novel and efficient selective mono-lithiation of a dihaloarene of the formula II or V: respectively, by an organo-lithium compound in the presence of a carbonyl reactant of the formula III: wherein R1 and R2 are as defined herein. In the process of the instant invention, the newly formed lithiated haloarene is sequentially quenched in situ by the carbonyl reactant to form said substituted haloarene. The process is suitable for batch or continuous flow systems. The substituted haloarenes produced by the process of the present invention are useful intermediates in the preparation of N-aryl or N-heteroaryl substituted pharmaceutically active compounds that include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated.